Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Ny bipolær radiofrekvensablationskniv i esophageale læsioner

2. november 2026 opdateret af: Fares Ayoub, Baylor College of Medicine

Prospektivt multicenterforsøg, der evaluerer effektiviteten og gennemførligheden af ​​en ny bipolar radiofrekvensablationskniv ved esophageal endoskopisk submucosal dissektion

Both Baylor St Luke's Medical Center and Mayo Scottsdale are considered endoscopic submucosal dissection (ESD) centers of excellence. The investigators at Baylor College of Medicine have previously reported our Esophageal ESD experience using the monopolar current knife. Moreover, the research team have previously reported on the clinical efficacy of the bipolar RFA knife during per-oral endoscopic myotomy (POEM) and colonic ESD. The goal of our study is to prospectively evaluate the efficacy, safety and feasibility of Esophageal ESD using a novel Bipolar-Current ESD device.

Studieoversigt

Detaljeret beskrivelse

Endoscopic submucosal dissection (ESD) is a novel technique for the removal of esophageal lesions or polyps with high-risk features. ESD is minimally invasive and allows the removal of esophageal polyps without resorting to morbid surgery. The process of ESD includes marking the lesions selected for removal, followed by submucosal injection of a lifting agent, then circumferential incisions using a specialized knife followed by submucosal dissection of the entire lesion.

Traditionally, knifes utilizing monopolar current were the preferred tools for endoscopic submucosal dissection. These knifes allow accurate dissection and excellent hemostasis. However, due to monopolar current generated heat, post coagulation syndrome can be seen in up to 8 to 40 % of patients. Post coagulation syndrome present with pain, fever and leukocytosis and requires supportive treatment with IV fluid and antibiotics. In addition, for large esophageal lesions, stricturing can occur after resection due to significant scar formation resulting from the tissue healing response to electrocautery. Almost all patients with >60% of the esophageal circumference removed via monopolar knives, will develop an esophageal stricture at some point. These patients require serial esophageal dilations, and although easily managed, its development can be quite troublesome to the patient. Nevertheless, ESD is still the preferred modality for removal of these lesions since it avoids the need for morbid surgery.

Recently, a novel Bipolar RFA knife was FDA approved for endoscopic submucosal dissection. The low voltage bipolar system allows for precise cutting of submucosa and muscle using substantially less energy, thereby limiting inadvertent remote thermal effects. Additionally, it allows aggressive coagulation of vessels without dissipation of large amounts of energy, thereby allowing more targeted therapy. Moreover, with the addition of an integrated injection needle, the knife now allows injection, safe cutting and coagulation in one device, potentially supporting more efficient dissection. Ultimately, due to less thermal effect on surrounding tissue, the bipolar knife may allow for removal of large esophageal lesions without causing major esophageal stricturing.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

50

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • Baylor College of Medicine
        • Ledende efterforsker:
          • Salmaan Jawaid, MD
        • Underforsker:
          • Mohamed Othman, MD
        • Kontakt:
        • Underforsker:
          • Tara Keihanian, MD
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

All patients undergoing intended ESD of precancerous lesions will be screened by study coordinators for preliminary eligibility and those who meet the inclusion criteria will be approach individually for further discussion about the study and obtaining informed consent.

Beskrivelse

Inclusion Criteria:

  • Patient is >18 years of age

  • Patient can provide informed consent

  • Patient is referred for resection of precancerous lesions meeting the following criteria:

    • Mucosal based polyp
    • Located gastroesophageal junction (GEJ) or proximal to GEJ
    • No previous endoscopic resection attempted (EMR or ESD)

Exclusion Criteria:

  • Patients with International Normalized Ratio (INR) >1.5 or Platelets <50,000
  • Lesions extending past GEJ
  • Subepithelial lesions

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: CASE_ONLY
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Treatment arm

Patients who were deemed eligible and signed the consent will undergo the removal of their esophageal precancerous lesion utilizing the novel bipolar knife during their endoscopic submucosal dissection (ESD).

Use of Speedboat™ Ultraslim for performing endoscopic submucosal dissection of esophageal lesions.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Technical success
Tidsramme: Day 1 (procedure day)

Defined as the ability to perform the entire dissection (procedure) with the novel bipolar knife

Day 1 (procedure day)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Speed of Endoscopic Submucosal Dissection
Tidsramme: During Procedure

The speed of endoscopic submucosal dissection as calculated by cm^2/hour

During Procedure
Number of instruments used
Tidsramme: During Procedure

Logging the variable equipment utilized during the procedure

During Procedure
Rate of muscle injury score
Tidsramme: During Procedure

As calculated by the Sydney Classification of Deep Mural Injury ranging from Type 0 - Type V with Type V as the most severe score.

During Procedure
Rate of post-electrocautery syndrome
Tidsramme: 24 hours, 2 weeks, and 4 weeks

Define as post-procedure abdominal pain, fevers, leukocytosis

24 hours, 2 weeks, and 4 weeks
Change in post-procedural pain score
Tidsramme: 24 hours, 2 weeks, and 4 weeks

As calculated by the visual analog pain scale to measure patient pain ranging from 0-10 with 10 being the most pain.

24 hours, 2 weeks, and 4 weeks
Rate of esophageal stricturing
Tidsramme: Assessed at any follow-up post-procedure endoscopies up to 6 months

Calculated by number of documented occurrences post-procedure for subjects

Assessed at any follow-up post-procedure endoscopies up to 6 months
Degree of scar formation
Tidsramme: Assessed at any follow-up post-procedure endoscopies up to 6 months

Scar formation that occurs in response to electrocautery

Assessed at any follow-up post-procedure endoscopies up to 6 months
Cost of dissection
Tidsramme: During Procedure

As calculated upon review of devices used during dissection procedure

During Procedure

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. oktober 2024

Primær færdiggørelse (Anslået)

30. juni 2027

Studieafslutning (Anslået)

31. december 2027

Datoer for studieregistrering

Først indsendt

21. juni 2024

Først indsendt, der opfyldte QC-kriterier

21. juni 2024

Først opslået (Faktiske)

26. juni 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. marts 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner